Telomir Pharmaceuticals Inc. (NASDAQ:TELO) experienced a significant boost in after-hours trading on Monday, with shares climbing 38.71% to reach $1.97. This surge followed the release of promising preclinical study results concerning its leading compound, Telomir-1.
The day’s trading began with a modest increase, as the stock edged up 1.43% during regular hours, closing at $1.42 based on data from Benzinga Pro.
Key Study Findings on DNA Methylation
In a filing with the SEC under Form 8-K, the Florida-based biotechnology company disclosed findings from research indicating that Telomir-1 demonstrated the ability to reverse abnormal deoxyribonucleic acid (DNA) methylation in aggressive prostate cancer models.
This reversal was significant as it restored the function of two essential tumor suppressor genes—MASPIN and RASSF1A—which are frequently silenced in cancer due to hypermethylation.
1. MASPIN’s Role: According to the company’s report, MASPIN plays several crucial roles in cancer defense mechanisms:
– It blocks tumor invasion and regulates cell migration and angiogenesis.
– It promotes apoptosis (programmed cell death).
– It enhances sensitivity to treatments.
Telomir-1 effectively reversed chemotherapy-induced DNA methylation, restoring MASPIN’s activity in living models (in vivo).
2. RASSF1A Functionality: RASSF1A is critical for:
– Regulating cell cycle control
– Promoting apoptosis
– Suppressing metastasis.
The findings indicated that Telomir-1 reduced RASSF1A methylation in a dose-dependent manner. Enhanced effects were observed particularly when Telomir-1 was administered alongside chemotherapy.
Ongoing Development
Telomir Pharmaceuticals has announced that it will continue its preclinical development alongside studies designed to enable Investigational New Drug (IND) applications, underscoring the ongoing commitment to advancing its pipeline.
Stock Performance Overview
Despite the recent uptick, TELO has struggled throughout the year, currently down 65.53% year-to-date. However, it has shown signs of recovery, posting a 15.45% gain in the past month. Over the last year, shares have fluctuated between $1.12 and $7.08, reflecting the volatility within the market.
The company currently holds a market capitalization of $45.84 million and has an average daily trading volume of 3.33 million shares. An analysis from Benzinga Edge Stock Rankings reveals a concerning negative price trend for TELO across all time frames, indicating potential challenges ahead.
Conclusion
As Telomir Pharmaceuticals continues to develop Telomir-1, the recent study results have sparked renewed interest in the stock. Investors and analysts will be closely watching how the company navigates its next steps in the challenging biotech landscape, particularly in regard to its ongoing preclinical studies. The potential impact on the treatment of aggressive prostate cancer could position Telomir-1 as a significant player in the field if future results align with these promising findings.
